West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
NCT Number: NCT07564908
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Observational
Chengdu, Sichuan, 610041, China
This study aims to retrospectively analyze the status and spatial heterogeneity of the tumor microenvironment (TME) in liver metastases from patients with CRLM, as well as the association between HGPs at the tumor-liver interface and postoperative recurrence following resection of liver metastases. Furthermore, this study seeks to explore the underlying mechanisms through which HGPs influence patient prognosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.
Time frame: OS is defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up, assessed up to 100 months.
OS was defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up.
Time frame: From the date of liver resection until the first occurrence of a measurable recurrence of the disease, or until death due to any cause (whichever occurs first), the assessment period can be up to 100 months.
The definition of recurrence-free survival is the time from the liver surgery to the first imaging evidence showing disease recurrence or death due to any cause, whichever occurs first.
Time frame: From the completion of HE staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.
The histopathological growth pattern of the tumor-liver interface.
Time frame: From the completion of mIHC staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.
Multiplex immunohistochemistry (mIHC) staining was performed on FFPE sections of liver metastases using two panels (Panel 1: CD4, CD8A, Foxp3, PD-L1, Panck; Panel 2: CD68, CD163, FAP-α, α-SMA, Panck), encompassing a total of nine immune cell markers. Using QuPath pathology imaging software, tissue sections were divided into the tumor center (defined as regions >500 μm from the liver-tumor interface) and the invasive tumor front (defined as a 1 mm region extending 500 μm on either side of the liver-tumor interface). Quantitative analysis of immune cell populations was performed in the tumor center, the invasive tumor front, and regions corresponding to different histopathological growth patterns.
Meng Qiu
Other
Acronym: CRLM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03485209
Bronchial Neoplasms, Carcinoma
Encinitas, California, United States
View Trial DetailsNCT06447662
Adenocarcinoma, Bronchial Neoplasms
Fayetteville, Arkansas, United States
View Trial DetailsNCT02484404
Breast Diseases, Breast Neoplasms
Bethesda, Maryland, United States
View Trial DetailsNCT05396846
Colonic Diseases, Colorectal Neoplasms
Ann Arbor, Michigan, United States
View Trial Details